Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 78 results:
Author Title [ Type(Desc)] Year
Filters: Author is Azoulay, L.  [Clear All Filters]
Journal Article
A. J. Klil-Drori, Yin, H., Abenhaim, H. A., Fort, G. G. du, and Azoulay, L., “Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer”, J Clin Psychiatry, vol. 78, pp. 714-719, 2017.
V. C. Brunetti, Reynier, P., Azoulay, L., Yu, O. H. Y., Ernst, P., Platt, R. W., and Filion, K. B., “SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study”, Pharmacoepidemiol Drug Saf, 2021.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., and Azoulay, L., “Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes”, Diabetes Care, vol. 42, pp. e150-e152, 2019.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., “Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study”, Br J Clin Pharmacol, 2019.
O. Yu, Azoulay, L., Yin, H., Filion, K. B., and Suissa, S., “Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia”, Am J Med, vol. 131, pp. 317.e11-317.e22, 2018.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study”, Bmj, vol. 362, p. k2693, 2018.
C. Santella, Renoux, C., Yin, H., Yu, O. H. Y., and Azoulay, L., “Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism”, Am J Epidemiol, 2019.
L. Azoulay, Schneider-Lindner, V., Dell'Aniello, S., Filion, K. B., and Suissa, S., “Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study”, Pharmacoepidemiol Drug Saf, vol. 19, pp. 343-50, 2010.
J. P. Fournier, Yin, H., Nessim, S. J., Montastruc, J. L., and Azoulay, L., “Tramadol for noncancer pain and the risk of hyponatremia”, Am J Med, vol. 128, pp. 418-25.e5, 2015.
J. P. Fournier, Azoulay, L., Yin, H., Montastruc, J. L., and Suissa, S., “Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain”, JAMA Intern Med, vol. 175, pp. 186-93, 2015.
D. Abrahami, McDonald, E. G., Schnitzer, M., and Azoulay, L., “Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study”, BMJ Open, vol. 10, p. e041529, 2020.
H. T. Ayele, Reynier, P., Azoulay, L., Platt, R. W., Cabaussel, J., Benayoun, S., and Filion, K. B., “Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study”, World J Urol, 2020.
L. Bensimon, Yin, H., Suissa, S., Pollak, M. N., and Azoulay, L., “Type 2 diabetes and the risk of mortality among patients with prostate cancer”, Cancer Causes Control, vol. 25, pp. 329-38, 2014.
F. Lapi, Azoulay, L., Kezouh, A., Benisty, J., Matok, I., Mugelli, A., and Suissa, S., “The use of antidepressants and the risk of chronic atrial fibrillation”, J Clin Pharmacol, vol. 55, pp. 423-30, 2015.
B. D. Fox, Azoulay, L., Dell'Aniello, S., Langleben, D., Lapi, F., Benisty, J., and Suissa, S., “The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension”, Can J Cardiol, vol. 30, pp. 1633-9, 2014.
J. Assayag, Pollak, M. N., and Azoulay, L., “The use of aspirin and the risk of mortality in patients with prostate cancer”, J Urol, vol. 193, pp. 1220-5, 2015.
L. Azoulay, Yin, H., Renoux, C., and Suissa, S., “The use of atypical antipsychotics and the risk of breast cancer”, Breast Cancer Res Treat, vol. 129, pp. 541-8, 2011.
L. Azoulay, Soldera, S., Yin, H., and Bouganim, N., “Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study”, Epidemiology, vol. 27, pp. 594-601, 2016.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
V. Mandilaras, Bouganim, N., Yin, H., Asselah, J., and Azoulay, L., “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
M. Tuccori, Wu, J. W., Yin, H., Majdan, A., and Azoulay, L., “The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes”, Diabetes Care, vol. 38, pp. 2083-9, 2015.
J. Rouette, Yin, H., Pottegard, A., Nirantharakumar, K., and Azoulay, L., “Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer”, Drug Saf, 2020.
R. Pradhan, Yin, H., Yu, O. H. Y., and Azoulay, L., “The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study”, Drug Saf, 2019.
B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus”, Cancer Epidemiol Biomarkers Prev, vol. 22, pp. 1877-83, 2013.
B. B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and the incidence of lung cancer in patients with type 2 diabetes”, Diabetes Care, vol. 36, pp. 124-9, 2013.
L. Azoulay, Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., and Suissa, S., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study”, Bmj, vol. 344, p. e3645, 2012.
K. Tascilar, Azoulay, L., Dell'Aniello, S., Bartels, D. B., and Suissa, S., “The Use of Telmisartan and the Incidence of Cancer”, Am J Hypertens, vol. 29, pp. 1358-1365, 2016.
C. Santella, Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., and Azoulay, L., “Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
[Page last reviewed 4 March 2021]